International law firm Dorsey & Whitney LLP won China Business Law Journal's Deals of the Year awards for 2023 in the “M&A,” “Intellectual Property,” and “Cross-Border Dispute Resolution” categories.
The annual Deals of the Year rankings by China Business Law Journal highlight the year’s most significant China-related deals and cases based on overall significance, complexity, and innovative nature.
Dorsey acted as co-counsel for Chow Tai Fook Enterprises (CTFE) on U.S. securities laws in a US$4.55 billion tender offer to buy NWS. The deal was the largest M&A transaction in Hong Kong in 2023 according to China Business Law Journal.
The firm also acted as co-counsel for I-Mab Biopharma, a Chinese and U.S.-based biotech company that won a significant victory in a years-long dispute with Tracon Pharmaceuticals. The ruling allows I-Mab to protect and further realise the value of its existing proprietary cancer therapies and innovative bispecific antibody combinations, enabling accelerated development and global partnerships.
Dorsey’s lead attorneys for the three awarded deals include Simon Chan, Joshua Colangelo-Bryan, Christopher L. Doerksen, Bruce Ewing, Jonathan Herman, Michael Keyes, and Ray Liu.
Deals of the Year awards are based on nominations and comments received by the China Business Law Journal from China-focused corporate counsel, senior managers, and legal professionals around the world, along with an evaluation of the winning firms’ landmark deals, cases, and other notable achievements.